Clinical trial
Miltefosine for Brazilian Visceral Leishmaniasis
NCT00378495 · AB Foundation, Other · Terminated
Key facts
| NCT number | NCT00378495 |
|---|---|
| Title | Miltefosine for Brazilian Visceral Leishmaniasis |
| Lead sponsor | AB Foundation, Other |
| Collaborators | AEterna Zentaris Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Kala Azar |
| Intervention type | Drug |
| Interventions | Miltefosine: initially 2.5 mg/kg/day for 28 days |
| Enrollment | 80 |
| Start date | Apr 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Sep 20, 2006 |
| Last update posted | Jul 12, 2016 |
| Countries | Brazil |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: